Human papillomavirus testing for primary cervical cancer screening
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
With our understanding of human papillomavirus (HPV) and cervical cancer, the availability of HPV testing, and the known limitations of cervical cytology, it is time to reassess cervical cancer screening technologies. This article reviews recent randomized trials comparing primary HPV testing with cervical cytology in screening for cervical cancer, and also analyzes the impact of the HPV vaccine on screening cytology.
- Nanda K, McCrory DC, Myers ER, et al.: Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Int Med 2000, 132:810–819.
- National Institutes of Health Consensus Statement: Cervical Cancer. April 1–3, 1996, 14:1–38.
- Walboomers JM, Jacobs MV, Manos MM, et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12–19. CrossRef
- Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al.: Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999, 354:20–25. CrossRef
- Koliopoulos G, Arbyn M, Martin-Hirsch P, et al.: Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007, 104:232–246. CrossRef
- Mayrand MH, Duarto-Franco E, Rodrigues I, et al.: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007, 357:1579–1588. CrossRef
- Mayrand MH, Duarte-Franco E, Coutlee F, et al.: Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer 2006, 119:615–623. CrossRef
- Naucler P, Ryd W, Törnberg S, et al.: Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007, 357:1589–1607. CrossRef
- Ronco G, Giorgi-Rossi F, Carozzi F, et al.: Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Instit 2008, 100:492–501. CrossRef
- Kitchener HC, Almonte M, Wheeler P, et al.: HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 2006, 95:56–61. CrossRef
- Kitchener HC, Almonte M, Desai M, et al.: The final results of the ARTISTIC Trial: a randomized trial of HPV testing and primary cervical screening. Acta Cytologic 2007, 51(Suppl 2):281.
- Kotaniemi-Talonen L, Anttila A, Nalial N, et al.: Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer 2008, 44:565–571. CrossRef
- Bulkmans NW, Berkhof J, Rozendaal L, et al.: Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomized controlled implementation trial. Lancet 2007, 370:1764–1772. CrossRef
- Harper DM, Franco EL, Wheeler CM, et al.: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004, 364:1757–1765. CrossRef
- Villa LL, Costa RL, Petta CA, et al.: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6:271–278. CrossRef
- The Future II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1915–1927. CrossRef
- Garland SM, Hernandez-Avila M, Wheeler CM, et al.: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356:1928–1943. CrossRef
- Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007, 56:1–24.
- Saslow D, Castle PE, Cox T, et al.: American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007, 57:7–28.
- Harper DM, Franco EL, Wheeler CM, et al.: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006, 367:1247–1255. CrossRef
- Villa LL, Costa RL, Petta CA, et al.: High sustained effi-cacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006, 95:1459–1466. CrossRef
- Ries L, Harkins D, Krapcho M, et al.: SEER cancer statistics review, 1975–2003. National Cancer Institute, 2006.
- Paavonen J, Jenkins D, Bosch FX, et al.: Efficacy of a prophylactic adjuvant bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomized controlled trial. Lancet 2007, 369:2161–2170. CrossRef
- Kulasingham SL, Myers ER: Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003, 290:781–789. CrossRef
- Saslow D, Runowicz CD, Solomon D, et al.: American Cancer Society Guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002, 52:342–362. CrossRef
- Smith RA, Cokkinides V, Brawley OW: Cancer screening in the United States, 2008: a review of current American Cancer Society Guidelines and cancer screening issues. CA Cancer J Clin 2008, 58:161–179. CrossRef
- Human papillomavirus testing for primary cervical cancer screening
Current Oncology Reports
Volume 10, Issue 6 , pp 533-537
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links